Abstract

The nucleotide adenosine-5′-monophosphate (AMP) can be released by various cell types and has been shown to elicit different cellular responses. In the extracellular space AMP is dephosphorylated to the nucleoside adenosine which can then bind to adenosine receptors. However, it has been shown that AMP can also activate A1 and A2a receptors directly. Here we show that AMP is a potent modulator of mouse and human dendritic cell (DC) function. AMP increased intracellular Ca2+ concentration in a time and dose dependent manner. Furthermore, AMP stimulated actin-polymerization in human DCs and induced migration of immature human and bone marrow derived mouse DCs, both via direct activation of A1 receptors. AMP strongly inhibited secretion of TNF-α and IL-12p70, while it enhanced production of IL-10 both via activation of A2a receptors. Consequently, DCs matured in the presence of AMP and co-cultivated with naive CD4+CD45RA+ T cells inhibited IFN-γ production whereas secretion of IL-5 and IL-13 was up-regulated. An enhancement of Th2-driven immune response could also be observed when OVA-pulsed murine DCs were pretreated with AMP prior to co-culture with OVA-transgenic naïve OTII T cells. An effect due to the enzymatic degradation of AMP to adenosine could be ruled out, as AMP still elicited migration and changes in cytokine secretion in bone-marrow derived DCs generated from CD73-deficient animals and in human DCs pretreated with the ecto-nucleotidase inhibitor 5′-(alpha,beta-methylene) diphosphate (APCP). Finally, the influence of contaminating adenosine could be excluded, as AMP admixed with adenosine desaminase (ADA) was still able to influence DC function. In summary our data show that AMP when present during maturation is a potent regulator of dendritic cell function and point out the role for AMP in the pathogenesis of inflammatory disorders.

Highlights

  • Different cell types such as activated platelets [1], neutrophils [2], and eosinophils [3] have been shown to release adenosine-59monophosphate (AMP)

  • Hydrolysis of ATP or ADP by ecto-ATPases (CD39) leads to the accumulation of AMP in the extracellular space, whereas AMP itself can be degraded by ecto59-nucleotidase (CD73) to adenosine which is a well characterized signaling molecule binding to different adenosine receptor subtypes

  • Stimulation of immature monocyte-derived dendritic cell (DC) resulted in a time- and dose- dependent increase in intracellular Ca2+ concentration (Fig. 1)

Read more

Summary

Introduction

Different cell types such as activated platelets [1], neutrophils [2], and eosinophils [3] have been shown to release adenosine-59monophosphate (AMP). Hydrolysis of ATP or ADP by ecto-ATPases (CD39) leads to the accumulation of AMP in the extracellular space, whereas AMP itself can be degraded by ecto59-nucleotidase (CD73) to adenosine which is a well characterized signaling molecule binding to different adenosine receptor subtypes. The biological effects of AMP include bronchoconstriction [4], stimulation of DNA synthesis, and mitogenesis [5]. Most of the effects elicited by AMP have been attributed to the fact that AMP can be degraded rapidly to adenosine. There is good evidence that AMP can directly bind to A1 and A2A receptors without being dephosphorylated to adenosine before [6,7]. GPR80 (GPR99) which has been claimed to be a receptor specific for AMP has turned out to be a receptor for citric acid cycle intermediates but not for AMP [8,9]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.